Home GE Healthcare Invests In FISH Technologies For Leukemia And Lymphoma Testing
 

Keywords :   


GE Healthcare Invests In FISH Technologies For Leukemia And Lymphoma Testing

2014-03-05 04:40:25| drugdiscoveryonline Home Page

GE Healthcare recently announced that Clarient Diagnostic Service, Inc., a GE Healthcare company, has made significant upgrades to its fluorescence in situ hybridisation (FISH) technologies to improve virtual analysis of testing results for a variety of blood diseases, including leukemia, lymphoma, myelodysplastic syndrome and myeloma

Tags: technologies testing fish healthcare

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 6
05.11Tropical Storm Rafael Wind Speed Probabilities Number 6
05.11Tropical Storm Rafael Public Advisory Number 6
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 6
05.11Why colouring clothes has a big environmental impact
05.11Atlantic Tropical Weather Outlook
More »